Published Research: Otsuka sheds light on Myelodysplasia Treatment in Australia with Patient-centric Intelligence
A recent study in eJHaem led by Anoop Enjeti, MD, PhD, in collaboration with Otsuka and Prospection, highlights the importance of treatment adherence and the need for more treatment options for Myelodysplastic Syndromes (MDS). It also showcases the critical role patient-centric intelligence can play in deepening understanding of treatment performance and patient behaviors, on the path to improving patient outcomes.
Real-world study of the use of azacitidine in myelodysplasia in Australia
Uncovering real-world insights into MDS treatment in Australia: Our study in eJHaem highlights the importance of treatment adherence and the need for innovative solutions.
Published Research: How Johnson & Johnson Innovative Medicine Used Patient-centric Intelligence in Japan to Understand Care Advancements for Pulmonary Arterial Hypertension
A recent study by Johnson & Johnson Innovative Medicine Asia Pacific, in collaboration with Prospection, utilised patient-centric intelligence (PCI) in Japan to evaluate the persistence of endothelin receptor antagonists in pulmonary arterial hypertension (PAH) treatment.
Real-World Study: Treatment Persistence in Pulmonary Arterial Hypertension Patients
The study analysed real-world data to compare treatment persistence and adherence among PAH patients on ERAs in Japan. Results showed significantly higher persistence with a medication compared to the other two medications.
Case Study: Treatment patterns in chronic lymphocytic leukaemia (CLL)
Learn how Prospection analysed real-world data and identified a shift towards newer novel agents for chronic lymphocytic leukemia (CLL) treatment, providing insights to support their client’s launch planning, submission modelling and market preparations for their new treatment. Prospection analysed treatment patterns, time to next treatment, duration of treatment, overall survival, and patient outcomes using the Australian Pharmaceutical Benefits Scheme (PBS) data, leveraging their experience in accessing and analysing oncology data in a real-world setting.
Case Study: Treatment patterns in mantle cell lymphoma (MCL)
Learn how Prospection helped a pharma client understand the real-world utilization of medicines for mantle cell lymphoma (MCL). With depth of experience and analytics expertise, Prospection was able to identify patient treatment profiles using Australian Pharmaceutical Benefits Scheme (PBS) data. The insights from the analysis guided important decisions around launch planning, submission modelling, and medical communications planning for the client.
Case Study: Rare disease (PAH) – Patient finding
The Prospection Platform helped a top pharmaceutical company simplify complex brand decision making surrounding Pulmonary Arterial Hypertension (PAH) to support patient programs with the aim to deliver earlier diagnoses and better referral programs. Our analysis identified anomalies across geographies for diagnosis and referrals by specialties. We equipped our client with these on-demand insights that enabled them to determine PAH stakeholders and decide how to achieve earlier diagnosis, better referrals, and improved patient outcomes.
Multiple Myeloma: the power of the patient journey
Multiple Myeloma (MM) Awareness Month takes place every March to raise awareness about this uncommon and complex blood cancer that can often be difficult to diagnose in its early stages and challenging to manage, despite…
How Global Patient-centric Intelligence Advances Rare Disease Insights
Patient-centric intelligence (PCI) is becoming increasingly important for improving outcomes for rare diseases, with over 300 million people living with them around the world. Treatment for these diseases can be expensive, time consuming and complex. From diagnosis to treatment, people living with rare diseases face common challenges, but by using real-world data from multiple countries, we can better understand treatment patterns and mobilize the real-world evidence needed to influence care pathways and bolster research. Increasing awareness and advocacy for rare disease research can help bring better outcomes for those affected.
Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia
This study analysed the utilization of ibrutinib, a BTK inhibitor, in treating chronic lymphocytic leukemia in Australia. It compared real-world data from the Pharmaceutical Benefits Scheme (PBS) to the RESONATE clinical trial, providing insights into ibrutinib use in the general community compared to the selected trial population.
Data helping Rare Cancers
An estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred Worldwide in 2020 (GLOBOCAN 2020). In Australia, cancer is the leading cause of health burden. More than 1 million people in…
Real World Evidence for Rare disease
Rare disease Day, recognises the 6,000+ identified, often life threatening, rare diseases*. Impacting over 300 million people worldwide, 72% of rare diseases are genetic, with 70% of those starting in childhood*. The low prevalence and…
